Lilly-linked brain metastases trial posts results; two baricitinib studies completeOct 30Weekly roundup, 4 itemsabemaciclibadagrasibUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruitsOct 15Weekly roundup, 5 itemsBoehringer Ingelheimempagliflozin
FDA approves efficacy supplement for Eli Lilly's OlumiantOct 9Regulatory decisionbaricitinibEli Lilly
Lilly posts Phase 3 orforglipron results; registers new MDD trial and five other updatesOct 2Weekly roundup, 10 itemsbaricitinibbrenipatideUpdated
AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
FDA approves efficacy supplement for Eli Lilly's Olumiant (baricitinib)Sep 25Regulatory decisionbaricitinibEli Lilly
Lilly posts orforglipron Phase 3 results; adds new early-phase studiesAug 14Weekly roundup, 6 itemsbaricitinibbrenipatide
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Lilly posts ACHIEVE-J results; Olumiant, Strattera labels updatedJul 2Weekly roundup, 5 itemsabemaciclibbaricitinib